Genetic heterogeneity in human astrocytomas: Spatial distribution of P16 and TP53 deletions in biopsies

Cancer Genetics and Cytogenetics

Volumn 113, Issue 2, 1999, Pages 115-119

  Steilen Gimbel, Heike ^a   Steudel, Wolf Ingo ^a   Feiden, Wolfgang ^a   Moringlane, Jean Richard ^a   Henn, Wolfram ^a   Zang, Klaus D ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; COSMID; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BIOPSY; BRAIN; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENETIC HETEROGENEITY; HOMOZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032790591     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(99)00013-8     Document Type: Article

References (28)

1. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harsham K., Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick N.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
2. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
3. Batra S.K., Rasheed B.K., Bigner S.H., Bigner D.D. Oncogenes and anti-oncogenes in human central nervous system tumors. Lab Invest. 71:1994;621-637.
4. Ueki K., Rubio M.-P., Ramesh V., Correa K.M., Rutter J.L., von Deimling A., Buckler A.J., Gusella J.F., Louis D.N. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet. 10:1994;1841-1845.
5. Newcomb E.W., Madonia W.J., Pisharody S., Lang F.F., Koslow M., Miller D.C. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol. 3:1993;229-235.
6. Westermark B., Nister M. Molecular genetics of human glioma. Curr Opin Oncol. 7:1995;220-225.
7. Coons S.W., Johnson P.C. Regional heterogeneity in proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol. 52:1993;609-618.
8. Coons S.W., Johnson P.C., Shapiro J.R. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. Cancer Res. 55:1995;1569-1577.
9. Linder S., Parrado C., Falkmer U.G., Blåsjö M., Sundelin P., von Rosen A. Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma. a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumor material Br J Cancer. 76:1997;54-59.
10. Löw M., Feiden W., Moringlane J.R., Zang K.D., Henn W. Detection of numerical aberrations in brain tumours by fluorescence in situ hybridization on smear preparations of small tumour biopsies. Neuropathol Appl Neurobiol. 20:1994;432-438.
11. Steilen-Gimbel H., Henn W., Kolles H., Moringlane J.-R., Feiden W., Steudel W.-I., Zang K.D. Early proliferation enhancement by monosomy 10 and intratumor heterogeneity in malignant human gliomas as revealed by smear preparations from biopsies. Genes Chromosom Cancer. 16:1996;180-184.
12. Kleihues P., Burger P.D., Scheithauer B.W. Histological Typing of Tumors of the Central Nervous System. 1993;World Health Organization International Histological Classification of Tumors. Springer, Berlin, New York.
13. Hopman A.H.N., Ramaekers F.C.S., Raap A.K., Beck J.L.M., Devilee P., van der Ploeg M., Vooijs G.P. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry. 89:1988;307-316.
14. Cleton-Jansen A.M., Collins N., Lakhani S.R., Weissenbach J., Devilee P., Cornelisse C.J., Stratton M.R. Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer. 72:1995;1241-1244.
15. Li Y.J., Hoang-Xuan K., Delattre J.-Y., Poisson M., Thomas G., Hamelin R. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene. 11:1995;597-600.
16. Emmert-Buck M.R., Lubensky I.A., Dong Q., Manickam P., Guru S.C., Kester M.B., Olufemi S.E., Agarwal S., Burns A.L., Spiegel A.M., Collins F.S., Marx S.J., Zhuang Z., Liotta L.A., Chandrasekharappa S.C., Debelenko L.V. Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Res. 57:1997;1855-1858.
17. Knudson A.G. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 45:1985;1437-1444.
18. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M.L., Cavenee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 355:1992;841-845.
19. Perry A., Norbori T., Ru N., Anderl K., Borell T.J., Mohapatra G., Feuerstein B.G., Jenkins R.B., Carson D.A. Detection of p16 gene deletions in gliomas. a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR J Neuropathol Exp Neurol. 56:1997;999-1008.
20. Burns K.L., Ueki K., Jhung S.L., Koh J., Louis D.N. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol. 57:1998;122-130.
21. Daumas-Duport C. Histological grading of gliomas. Curr Opin Neurol. 5:1992;924-931.
22. Cairans P., Mao L., Merlo A., Lee D.J., Schwab D., Eby Y., Tokino K., van der Riet P., Blaugrund J.E., Sidransky D. Rates of p16 (MTS1) mutation in primary tumors with 9p loss. Science. 265:1994;415-416.
23. Jen J., Haper W., Bigner S.H., Bigner D.D., Papadopoulos N., Markowitz S., Willson J.K.V., Kinzler K.W., Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54:1994;6353-6358.
24. Moulton T., Samara G., Chung W.Y., Yuang L., Desai R., Sisti M., Bruce J., Tycko B. MTS1/p16/DKN2 lesions in primary glioblastoma multiforme. Am J Pathol. 146:1995;613-619.
25. Sonoda Y., Yoshimoto T., Sekiya T. Homozygous deletion of the MTS1/p16 and MTS1/p15 genes and amplification of the CDK4 gene in glioma. Oncogene. 11:1995;2145-2149.
26. Tsuzuki T., Tsunoda S., Konishi N., Hiasa Y., Nakamura M. Alterations of retinoblastoma, p53 p16(CDKN2), and p15 genes in human astrocytomas. Cancer. 78:1996;287-293.
27. Schmidt E.E., Ichimura K., Messerle K.R., Goike H.M., Collins V.P. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumors. Br J Cancer. 75:1997;2-8.
28. Kyritsis A.P., Zhang B., Zhang W., Xiao M., Takeshima H., Bondy M.L., Cunningham J.E., Levin V.A., Bruner J. Mutations of the p16 gene in gliomas. Oncogene. 12:1996;63-67.